Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis (adjusted HR, 9.09 [95% CI, 1.25-66.00]), bowel obstruction (HR, 4.22 [95% CI, 1.02-17.40]), and gastroparesis (HR, 3.67 [95% CI, 1.15-11.90) but not biliary disease (HR, 1.50 [95% CI, 0.89-2.53])
Disclaimer: The contents of the Westlake Dermatology website, including text, graphics, and images, are for informational purposes only and are not intended to substitute for direct medical advice from your physician or other qualified professional.
Research articles View all articles
Some Anthem Blue Cross Blue Shield plans in Michigan may cover weight loss treatment, including medical weight management visits and FDA-approved obesity medications, depending on your specific plans benefit structure
Nausea, vomiting, and gastrointestinal discomfort are reported more often by female patients, she explains